NEW YORK, Sept. 12, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced that the Company will participate in two events at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting in Munich, Germany -- the largest international forum for minimally invasive image-guided therapy, with more than 5,600 interventional radiologists in attendance.
On Monday, September 12, James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine and a lead Principal Investigator of the Company's recently completed Phase 2 clinical trial, will present results from the neuroendocrine tumor (mNET) cohort. The late-breaking abstract will be presented as part of CIRSE's Oncologic Intervention oral abstract session.
The Company will also sponsor a symposium to be held on Tuesday, September 13th which will feature three U.S. physicians with direct experience with Delcath's chemosaturation system and be moderated by Dr. Riccardo Lencioni—Associate Professor of Radiology and Head of Diagnostic Imaging and Intervention in the Department of Liver Transplantation, Hepatology and Infectious Diseases of the University of Pisa.
"These conferences play an important role in our strategy to grow sales in Europe, our first commercial territory," said Eamonn P. Hobbs, President & CEO of Delcath. "It is fitting that we present our results for the NET cohort of our Phase 2 trial there, as CHEMOSAT is approved in that market for the treatment of all liver cancers. We are also pleased to host this symposium, allowing the attending physicians to learn from the clinical experience of their U.S. colleagues."
About Delcath Systems
Delcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to obtain regulatory approval in foreign markets and adoption and use of the chemosaturation system in such markets, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Doug Sherk/Gregory Gin
SOURCE Delcath Systems, Inc.